Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Adcetris

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

Succinct and ecancer team up on oncology education events

Will work together to support HCPs

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

- PMLiVE

Pfizer signs $2.85bn immuno-oncology alliance

Will jointly develop Merck KGaA's lead anti-PD-L1 drug

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

- PMLiVE

FDA votes to keep severe warning on Pfizer’s Chantix

Will not relax anti-smoking drug's side effect warning

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links